Perioperative Enfortumab Vedotin plus Pembrolizumab Cost-Effective in Cisplatin-Ineligible MIBC
This industry-funded US cost-utility analysis provides the first published economic evaluation of perioperative enfortumab vedotin plus pembrolizumab in cisplatin-ineligible or cisplatin-declining muscle-invasive bladder cancer, informing formulary and payer decisions after the November 2025 FDA approval.
📅 Journal publication: Dec 2026(online Aug 18, 2026)·Last updated: Sep 26, 2026
Pembrolizumab plus enfortumab vedotin stands out as cost-effective for bladder cancer.
Patients with muscle-invasive bladder cancer (MIBC) who are ineligible or decline cisplatin have limited treatment options. Pembrolizumab with enfortumab vedotin (EV+Pem) offers a potential cost-effective alternative. EV+Pem improved quality-adjusted life-years (QALYs) by 2.56 and life-years by 3.08 compared to surgery with or without adjuvant nivolumab. The incremental cost-effectiveness ratio (ICER) was $52,117 per QALY. The treatment was cost-effective under a $100,000 per QALY threshold. Limitations include uncertainties in long-term survival projections and changing post-progression treatment patterns. EV+Pem provides a cost-effective treatment option for cisplatin-ineligible patients with MIBC.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Hill-McManus D, Lai Y, Bensimon AG, Young J, Reeve K, Tzontcheva A, Squires P, Li H, Ramamurthy C, Mossanen M
Citation:Hill-McManus D, Lai Y, Bensimon AG, et al. Cost-effectiveness of perioperative pembrolizumab plus enfortumab vedotin for cisplatin-ineligible or cisplatin-declining patients with muscle-invasive bladder cancer in the United States. Journal of medical economics. 2026;29(1):2161-2176. doi:10.1080/13696998.2026.2713865